Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer

The anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with chemotherapy is a standard of care in the first-line treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) and has demonstrated efficacy in later lines. Progressive disease (PD) occurs wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Richard M, Montagut, Clara, Wainberg, Zev A, Ronga, Philippe, Audhuy, François, Taieb, Julien, Stintzing, Sebastian, Siena, Salvatore, Santini, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950648/
https://www.ncbi.nlm.nih.gov/pubmed/29765773
http://dx.doi.org/10.1136/esmoopen-2018-000353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950648/
https://www.ncbi.nlm.nih.gov/pubmed/29765773
http://dx.doi.org/10.1136/esmoopen-2018-000353

Ejemplares similares